Rhapsido
Rhapsido ingredients
| Active ingredient | Strength |
|---|---|
| Remibrutinib | 25 mg/1 |
What Rhapsido is used for
The FDA lists the approved uses on the official label (below). In the EU, remibrutinib is approved as Rhapsido for:
Rhapsido is indicated for the treatment of chronic spontaneous urticaria (CSU) in adult patients with inadequate response to H1 antihistamine treatment.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Rhapsido
- Generic name
- Remibrutinib
- Made by
- Novartis Pharmaceuticals Corporation
- Forms
- Tablet
- Given
- Oral
- Drug class
- Kinase Inhibitor
- FDA approval
- New drug application (NDA) NDA218436
- On the US market since
- 2025
Official information
- MedlinePlus drug information (search for Remibrutinib)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Rhapsido?
Rhapsido (Remibrutinib) is a cancer medicine made by Novartis Pharmaceuticals Corporation, approved by the US FDA.
What are the ingredients of Rhapsido?
Rhapsido contains Remibrutinib (25 mg/1).
Is Rhapsido approved in Europe?
The same active substance is approved in the EU as Rhapsido.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA